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share the work provObjectives: We assessed the association between the timing of pregnancy with the risk
of postpartum virologic failure and loss from HIV care in South Africa.
Design: This is a retrospective cohort study of 6306 HIV-positive women aged 15–49 at
antiretroviral therapy (ART) initiation, initiated on ART between January 2004 and
December 2013 in Johannesburg, South Africa.
Methods: The incidence of virologic failure (two consecutive viral load measurements
of>1000 copies/ml) and loss to follow-up (>3 months late for a visit) during 24 months
postpartum were assessed using Cox proportional hazards modelling.
Results: The rate of postpartum virologic failure was higher following an incident
pregnancy on ART [adjusted hazard ratio 1.8, 95% confidence interval (CI): 1.1–2.7]
than among women who initiated ART during pregnancy. This difference was sustained
among women with CD4þ cell count less than 350 cells/ml at delivery (adjusted hazard
ratio 1.8, 95% CI: 1.1–3.0). Predictors of postpartum virologic failure were being
viremic, longer time on ART, being 25 or less years old and low CD4þ cell count and
anaemia at delivery, as well as initiating ART on stavudine-containing or abacavir-
containing regimen. There was no difference postpartum loss to follow-up rates
between the incident pregnancies group (hazard ratio 0.9, 95% CI: 0.7–1.1) and those
who initiated ART in pregnancy.
Conclusion: The risk of virologic failure remains high among postpartum women,
particularly those who conceive on ART. The results highlight the need to provide
adequate support for HIV-positive women with fertility intention after ART initiation
and to strengthen monitoring and retention efforts for postpartum women to sustain the
benefits of ART. Copyright  2017 The Author(s). Published by Wolters Kluwer Health, Inc.AIDS 2017, 31:1593–1602Keywords: antiretroviral therapy, antiretroviral therapy retention, HIV
treatment, postpartum period, pregnancy, South AfricaIntroduction
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1594 AIDS 2017, Vol 31 No 11HIV made provisions to initiate all HIV-positive pregnant
and breastfeeding women on lifelong antiretroviral
therapy (ART) upon HIV diagnosis [5]. Although this
policy further increased the ART coverage in this
population, long-term ART success will depend on their
ability to attain sustained virologic suppression.
The PMTCT programmes play a critical role in the
diagnosis and ART initiation of HIV-positive women.
However, the programme’s strong focus on protecting the
baby frames the ART experience of many HIV-positive
women [6–9]. As a result, the motivation of women
initiated on ART in the context of PMTCT to adhere to
ART and remained in HIV care wanes gradually after
delivery [10–12]. Although this is well documented
among women who initiate ART during pregnancy
(prevalent pregnancies at ART initiation), far less has been
written about women who conceive while receiving
ART (incident pregnancies). The 2013 South African
national ANC survey showed that the majority (73.5%) of
primiparous women who tested HIV-positive in ANC
had prior knowledge of their HIV status but the
proportion with prior ART exposure is unclear [2].
Certainly, as South Africa scales up the ‘treat-all’ strategy,
many more HIV-positive women will be receiving ART
at conception [13,14].
To date, few studies have quantified the postpartum risk of
virologic failure because of viral load data limitations in
most resource-limited settings. Furthermore, the ques-
tion of whether initiating ART before a pregnancy
improves postpartum retention and virologic outcomes
has not been sufficiently explored. Understanding
predictors of postpartum virologic failure and loss from
HIV care among treatment experienced women who
conceive on ART is necessary to inform interventions to
improve postpartum retention in care and ART
adherence among women with fertility intentions after
ART initiation.
In this article, we aim to assess whether the timing of
ART initiation in relation to pregnancy start has some
bearing on the risk of virologic failure and the risk
of becoming lost to follow-up (LTFU) in the first
2 years postpartum.Methods
Study population
We conducted a cohort study using prospectively
collected, anonymized medical records of HIV-infected
adult women (18–49 years old at ART initiation)
initiated on a standard first-line ART regimen according
to South African guidelines between 1 January 2004 and
31 December 2013, at three nongovernmental organiz-
ations (NGO) and seven public ART clinics that receivetechnical support from right to care, a nonprofit
organization in Johannesburg, South Africa. The first
South African ART guidelines in 2004 made provisions
for one first-line regimen including stavudine (d4T),
lamivudine (3TC), efavirenz (EFV) or nevirapine (NVP)
in the case of contraindications to EFV [15]. In 2010, the
standard first-line regimens were updated to substitute
d4T with tenofovir (TDF) as the first option for new
patients, include zidovudine (ZDV) as part of first-line
ART in which TDF was contraindicated and use
emtricitabine (FTC) as an alternative for 3TC [16]. In
2013, abacavir (ABC) was added as an option in cases of
contraindications to TDF, ZDVand d4T in first-line ART
[17].
Clinical data from the ART clinics were captured on site
and stored in an electronic patient-management system,
TherapyEdge-HIV (Advanced Biologic Laboratories,
SA, Luxembourg). Additional clinical and laboratory
data were obtained from electronic records held by the
National Health Laboratory Services. Data were fully
anonymized for analysis. The final analytic data set
included only women who had at least one recorded viral
load measurement during the period of observation.
The primary exposure event was having a first (ever)
pregnancy lasting at least 7 months and ending before 31
December 2013 that resulted in a live birth. Unexposed
women (no recorded pregnancy) were matched to
exposed women on age at ART initiation, year of
ART initiation and time on ART at delivery. Time on
ART for exposed women was measured from ART
initiation to the date of delivery. The observation period
for unexposed women (pseudo-postpartum period)
began at the delivery date of their matched exposed
woman.
The data set was closed on 31 December 2015, allowing
for 24 months of postpartum (or equivalent period on
ART for the unexposed) follow-up. Up to two
unexposed women were matched to each exposed
woman. Ethics approval for the data review was obtained
from the Human Research Ethics Committee of the
University of Witwatersrand (M140201) as well as Boston
University Institutional Review Board (H-29768).
Analytic variables
The secondary exposure variable was created by further
categorizing exposed women by when, in relation to the
pregnancy start date, ART was initiated as unexposed
women (no recorded pregnancy), women conceived
while receiving ART (incident pregnancy) and women
who initiated ART during pregnancy (prevalent preg-
nancy).
The primary outcome was virologic failure (defined
as having two consecutive viral load measurements
>1000 copies/ml, and the first failing viral load occurring
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24 months postpartum or pseudo-postpartum for un-
exposed women (six). The secondary outcome was
postpartum LTFU from HIV care, defined as being at
least 3 months late for a scheduled visit during the
observation period.
Potential confounders included were demographic
variables as well as clinical and laboratory variables
measured closest to the date of delivery either in the last
trimester of the pregnancy or no more than 3 months after
delivery or baseline for the unexposed, including BMI,
CD4þ cell counts, ARTregimen and haemoglobin (Hb).
BMI was categorized as underweight (BMI< 18.5),
normal (18.5BMI< 25), overweight (25BMI< 30)
and obese (BMI 30). Anaemia was defined as an Hb
value below 11.5 g/dl. CD4þ (measured in cells/ml)
was categorized as less than199, 200–350 and more than
350 cells/ml. Viral suppression was defined as having a
viral load measurement less than 50 copies/ml.
Follow-up time
Person-time accrued from the date of delivery (con-
sidered as baseline time point) for postpartum women or
their matched baseline date for unexposed women.
Women were followed until the outcome of interest, the
last date seen at the clinic during the first 2 years after the
baseline date (for those who died, were LTFU or
transferred out) or 31 December 2015, whichever
came first.
Statistical analysis
Baseline characteristics were described using medians and
interquartile ranges (IQRs) for continuous variables and
percentages for categorical variables stratified by preg-
nancy status. Computed incidence of virologic failure or
LTFU was expressed as rates per 100 person-years. Cox
proportional hazard models were used to explore
predictors of postpartum virologic failure and LTFU
separately. We then conducted a Cox regression stratified
by timing of the first pregnancy to examine whether
predictors of postpartum virologic failure or LTFU
among women who conceive on ART differ from those
of women who initiate ART during pregnancy. Variables
associated with virologic failure or LTFU in crude Cox
proportional hazards models (P< 0.10) in the postpartum
period were included in multivariate models. Also
included were variables that changed the hazard ratio
for the exposure of interest by more than10% and are
known not to be on the causal pathway or colliders.
Schoenfeld residuals were used to test for adherence to the
proportional hazard assumption. Kaplan–Meier curves
were used to compare progression to first virologic failure
or LTFU event in the postpartum period among women
with high baseline CD4þ (>350 cells/ml) to women with
low baseline CD4þ (350 cells/ml), stratified by timing
of pregnancy. Data analysis was conducted using STATA
version 14 (StataCorp, College Station, Texas, USA).Results
Baseline demographic characteristics of study
sample
The data set included 7953 women. From these, 1128
(14.2%) with missing scheduled visits after delivery and
519 (6.5%) with missing postpartum viral load measure-
ments were excluded from the final analytic data set.
Among the excluded women, 278 of 1647 (16.9%) were
transferred within the first 3 months after delivery, and 44
of 1647 (2.7%) women died within 90 days of delivery.
Table 1 presents the demographic and clinical charac-
teristics of the study sample consisting of 6306 women,
2403 (38.1%) were unexposed, 1953 (31.0%) had an
incident pregnancy on ART and 1950 (30.9%) had a
prevalent pregnancy at ART initiation. The overall
median age at the start of observation was 31.2 years
(IQR: 27.7–35.0). The prevalent pregnancy group was
slightly younger at delivery (median 29.7 years, IQR:
26.4–33.6) compared with the incident pregnancy group
(median 32.3, IQR: 28.9–35.6). Furthermore, the
proportion of school attenders with at least a grade 12
level of education was markedly higher among women
with an incident pregnancy (67.9%) than women with a
prevalent pregnancy (50.3%). Unemployment rates were
similar across exposure categories with an average rate of
61.9%.
Baseline clinical characteristics of study sample
Overall, 30.2% of women initiated ART on a combi-
nation of 3TC/FTC, TDF and EFV or NVP, only 9.7%
were initiated on a regimen of ZDV, 3TC and EFV/NVP,
and 59.8% were initiated on d4T, 3TC and EFV/NVP.
Although the majority (93.6%) of women with prevalent
pregnancy and 80.2% of unexposed women remained on
their first regimen throughout the pregnancy, only 53.7%
of women with incident pregnancies were still on their
first regimen with 11.2% permanently switched to
second-line ART at delivery. Overall, 39.8% of post-
partum (exposed) women had detectable viral RNA
(>50 copies/ml) at delivery. Anaemia at delivery was
most common in the prevalent pregnancy group (29.6,
26.3 and 50.5% among unexposed women, incident
pregnancy and prevalent pregnancy, respectively). Over-
all, 47.0% had baseline CD4þ at least 350 cells/ml, 43.1%
among unexposed women, 61.9% among the incident
pregnancy group and 38.0% among prevalent pregnancy
group.
Predictors of virologic failure 24 months
postpartum
Table 2 and Fig. 1 show rates and predictors of virologic
failure in the study sample. Study patients were followed
up for an average of 1.6 years (SD 0.6). Overall, 510
(8.1%) women experienced virologic failure in the
10 091.5 person-years of observation [incidence rate
5.1/100 person-years, 95% confidence interval (CI):
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Table 1. Demographic and baseline clinical characteristics of the study sample.
Women with no
recorded pregnancy
Women with
incident pregnancy
Women with
prevalent pregnancy Total
n (col %) n (col %) n (col %) n (col %)
N¼2403 N¼1953 N¼1950 N¼6306
Average follow-up time, mean years (SD) 1.6 (0.6) 1.7 (0.5) 1.5 (0.6) 1.6 (0.6)
Race
Black 2334 (98.3) 1917 (98.6) 1896 (98.6) 6147 (98.5)
Other 41 (1.7) 28 (1.4) 27 (1.4) 96 (1.5)
Age at delivery/baseline
Under 25 289 (12.0) 120 (6.1) 323 (16.6) 732 (11.6)
25–29.9 669 (27.8) 518 (26.5) 689 (35.3) 1876 (29.7)
30–39.9 1327 (55.2) 1223 (62.6) 867 (44.5) 3417 (54.2)
40–49.9 118 (4.9) 91 (4.7) 71 (3.6) 280 (4.4)
Highest level of education at ART initiation
Primary school 213 (9.2) 143 (7.6) 121 (6.4) 477 (7.9)
Some secondary school 528 (22.8) 260 (13.8) 525 (27.9) 1313 (21.6)
Grade 12 completed 971 (42.0) 801 (42.7) 627 (33.4) 2399 (39.5)
Postmatric 48 (2.1) 53 (2.8) 27 (1.4) 128 (2.1)
No schooling 552 (23.9) 621 (33.1) 580 (30.9) 1753 (28.9)
Employment status at ART initiation
Employed 838 (36.8) 680 (36.1) 770 (41.9) 2288 (38.1)
Unemployed 1441 (63.2) 1203 (63.9) 1069 (58.1) 3713 (61.9)
ART site
Clinic in hospital complex 1055 (43.9) 1037 (53.1) 510 (26.2) 2602 (41.3)
Local primary care clinic 949 (39.5) 438 (22.4) 593 (30.4) 1980 (31.4)
NGO-run clinic 398 (16.6) 478 (24.5) 847 (43.4) 1723 (27.3)
Initial first-line ART regimen
3TC/FTCþTDFþ EFV/NVP 753 (31.3) 309 (15.8) 843 (43.2) 1905 (30.2)
ZDVþ3TCþ EFV/NVP 146 (6.1) 112 (5.7) 355 (18.2) 613 (9.7)
d4Tþ3TCþ EFV/NVP 1491 (62.0) 1530 (78.3) 751 (38.5) 3772 (59.8)
3TCþABCþ EFV/NVP 13 (0.5) 2 (0.1) 1 (0.1) 16 (0.3)
ART regimen changes by the time of delivery (or equivalent matched time)
First-line regimen preserved 1927 (80.2) 1049 (53.7) 1826 (93.6) 4802 (76.2)
First-line drug substitution 346 (14.4) 619 (31.7) 50 (2.6) 1015 (16.1)
Switched to second-line ART 56 (2.3) 219 (11.2) 15 (0.8) 290 (4.6)
Treatment interrupted 74 (3.1) 66 (3.4) 59 (3.0) 199 (3.2)
Among those who interrupted ART
Overall length of treatment interruption,
median months (IQR)
12.7 (6.6–21.2) 5.8 (3.9–11.4) 5.7 (2.7–14.1) 8.0 (4.1–16.2)
Period of ART interruption in pregnancy,
median months (IQR)
4.6 (1.4–9.0) 0.6 (0–4.5) 0 (0–0.5) 1.0 (0–5.0)
Period of interruption after delivery,
median months (IQR)
6.3 (2.4–13.6) 4.7 (3.0–7.3) 6.3 (2.0–14.8) 5.4 (2.4–12.8)
New regimen after treatment interruption
3TC/FTCþTDFþ EFV/NVP 32 (43.2) 18 (27.7) 25 (42.4) 75 (37.9)
ZDVþ3TCþ EFV/NVP 3 (4.1) 9 (13.9) 6 (10.2) 18 (9.1)
d4Tþ3TCþ EFV/NVP 25 (33.8) 19 (29.2) 22 (37.3) 66 (33.3)
Second-line (three ARVs with LPVr/ATVr) 6 (8.1) 16 (24.6) 5 (8.5) 27 (13.6)
Other 8 (10.8) 3 (4.6) 1 (1.7) 12 (6.1)
Time on ART before delivery (or equivalent matched time)
3 months or less 563 (23.4) 0 1390 (71.3) 1953 (31.0)
4–6 months 432 (18.0) 0 440 (22.6) 872 (13.8)
7–12 months 428 (17.8) 163 (8.3) 120 (6.2) 711 (11.3)
13–24 months 527 (21.9) 862 (44.1) 0 1389 (22.0)
25 months or longer 453 (18.9) 928 (47.5) 0 1381 (21.9)
BMI up to 3 months before or after delivery (or equivalent matched time)
Underweight 135 (7.5) 21 (1.2) 19 (1.1) 175 (3.3)
Normal 876 (48.7) 570 (31.7) 553 (31.6) 1999 (37.4)
Overweight 499 (27.8) 719 (39.9) 697 (39.8) 1915 (35.8)
Obese 288 (16.0) 490 (27.2) 483 (27.6) 1261 (23.6)
Anaemic up to 3 months before or after delivery (or equivalent matched time)
No 1103 (70.4) 1075 (73.7) 777 (49.5) 2955 (64.3)
Yes 463 (29.6) 383 (26.3) 794 (50.5) 1640 (35.7)
CD4þ cell count up to 3 months before or after delivery (or equivalent matched time)
Under 200 464 (25.3) 148 (9.9) 462 (28.2) 1074 (21.6)
200–349 579 (31.6) 420 (28.2) 555 (33.9) 1554 (31.3)
350 or higher 789 (43.1) 923 (61.9) 622 (38.0) 2334 (47.0)
Unsuppressed viral load (50 copies/ml) up to 3 months before or after delivery (or equivalent matched time)
No 1149 (63.1) 1054 (64.6) 913 (55.7) 3116 (61.2)
Yes 672 (36.9) 577 (35.4) 726 (44.3) 1975 (38.8)
Viral load 400 copies/ml up to 3 months before or after delivery (or equivalent matched time)
No 1464 (80.4) 1359 (83.3) 1226 (74.8) 4049 (79.5)
Yes 357 (19.6) 272 (16.7) 413 (25.2) 1042 (20.5)
Baseline/equivalent matched time: end of first pregnancy for exposed and equivalent time on ART for matched nonexposed women. 3TC,
lamivudine; ABC, abacavir; ARV, antiretroviral; AZT, zidovudine; d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; LPVr, lopinavir; NGO,
nongovernmental organizations; NVP, nevirapine; IQR, interquartile range; TDF, tenofovir; ZDV, zidovudine.
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Table 2. Predictors of virologic failure 24 months postpartum among HIV-positive women receiving antiretroviral therapy in Johannesburg,
South Africa.
Virologic
failure
Person-
years
Rate per100
PY (95% CI)
Total sample Women with
incident pregnancy
Women with
prevalent pregnancy
Crude HR (95% CI) aHR (95% CI) aHR (95% CI) aHR (95% CI)
Total sample 510 (8.1) 10 091.5 5.1 (4.6–5.5)
Timing of pregnancy
No recorded pregnancy 198 (8.2) 3870.1 5.1 (4.5–5.9) 1 1
Incident pregnancy 188 (9.6) 3284.9 5.7 (5.0–6.6) 1.1 (0.9–1.4) 1.3 (1.0–1.8)
Prevalent pregnancy 124 (6.4) 2936.4 4.2 (3.5–5.0) 0.8 (0.7–1.0) 0.7 (0.5–1.0)
Age at baseline
Under 25 73 (10.0) 1085.6 6.7 (5.3–8.5) 1 1 1 1
25–29.9 166 (8.8) 2947.8 5.6 (4.8–6.6) 0.8 (0.6–1.1) 0.8 (0.6–1.1) 0.9 (0.5–1.7) 0.6 (0.3–1.3)
30–39.9 257 (7.5) 5583.2 4.6 (4.1–5.2) 0.7 (0.5–0.9) 0.7 (0.5–0.9) 0.6 (0.4–1.1) 0.9 (0.5–1.7)
40–49.9 14 (5.0) 473.2 3.0 (1.8–5.0) 0.4 (0.2–0.8) 0.3 (0.1–0.7) 0.2 (0.1–0.8) 0.4 (0.1–1.7)
Highest level of education at ART initiation
Primary school 43 (9.0) 744.2 5.8 (4.3–7.8) 1
Some secondary school 96 (7.3) 1974.3 4.9 (4.0–5.9) 0.8 (0.6–1.2)
Grade 12 completed 203 (8.5) 3875.3 5.2 (4.6–6.0) 0.9 (0.7–1.3)
Postmatric 11 (8.6) 210.5 5.2 (2.9–9.4) 0.9 (0.5–1.8)
No schooling or unknown 141 (8.0) 2908.2 4.8 (4.1–5.7) 0.8 (0.6–1.2)
Employment status at ART initiation
Employed 160 (7.0) 3777.8 4.2 (3.6–4.9) 1 1 1 1
Unemployed 333 (9.0) 5847.9 5.7 (5.1–6.3) 1.3 (1.1–1.6) 1.2 (0.9–1.5) 1.0 (0.7–1.4) 1.2 (0.8–1.9)
ART site
Clinic in hospital complex 219 (8.4) 4258.7 5.1 (4.5–5.9) 1
Local primary care clinic 167 (8.4) 3012.6 5.5 (4.8–6.5) 1.1 (0.9–1.3)
NGO-run clinic 124 (7.2) 2819.2 4.4 (3.7–5.2) 0.9 (0.7–1.1)
First ever ART regimen
TDFþ3TC/FTCþ EFV/NVP 130 (6.8) 2845.0 4.6 (3.8–5.4) 1 1 1 1
ZDVþ3TCþ EFV/NVP 44 (7.2) 1001.8 4.4 (3.3–5.9) 1.0 (0.7–1.3) 1.0 (0.7–1.6) 0.9 (0.3–3.0) 1.2 (0.6–2.3)
d4Tþ3TCþ EFV/NVP 332 (8.8) 6221.6 5.3 (4.8–5.9) 1.2 (0.9–1.4) 0.7 (0.4–1.2) 2.3 (1.2–4.4) 0.2 (0.1–0.8)
ABCþ3TCþ EFV/NVP 4 (25.0) 23.1 17.3 (6.5–46.1) 3.8 (1.4–10.3) 0.9 (0.2–3.5) 5.5 (1.1–27.0) –
ART regimen changes by delivery/baseline
First-line regimen preserved 377 (8.0) 7600.6 5.0 (5.9–5.5) 1 1 1 1
First-line drug substitution 74 (7.3) 1730.9 4.3 (3.4–5.4) 0.9 (0.7–1.1) 0.8 (0.6–1.2) 1.0 (0.7–1.5) 0.6 (0.1–2.5)
Switched to second-line ART 27 (9.3) 446.4 6.0 (4.1–8.8) 1.2 (0.8–1.8) 0.8 (0.5–1.3) 1.0 (0.6–1.7)
Treatment interrupted 32 (16.1) 313.6 10.2 (7.2–14.4) 2.1 (1.4–2.9) 1.1 (0.7–1.9) 1.2 (0.5–2.6) 0.7 (0.2–2.9)
Time on ART before delivery/baseline
3 months or less 136 (7.0) 2973.5 4.6 (3.9–5.4) 1 1 1
4–6 months 61 (7.0) 1333.2 4.6 (3.6–5.9) 1.0 (0.8–1.3) 1.6 (1.1–2.3) 1.8 (1.0–3.1)
7–12 months 59 (8.3) 1160.5 5.1 (3.9–6.6) 1.0 (0.7–1.4) 1.4 (0.9–2.2) 1 3.0 (1.4–6.2)
13–24 months 147 (10.6) 2300.8 6.4 (5.4–7.5) 1.1 (0.8–1.5) 2.0 (1.3–3.1) 1.8 (1.0–3.5)
25 months or longer 107 (7.7) 2323.5 4.6 (3.8–5.6) 1.4 (1.1–1.8) 1.7 (1.1–2.9) 1.5 (0.7–2.9)
BMI (up to 3 months before or after baseline)
Underweight 15 (8.6) 265.9 5.6 (3.4–9.4) 1.1 (0.6–1.8)
Normal 171 (8.6) 3190.3 5.4 (4.6–6.2) 1
Overweight 138 (7.2) 3076.3 4.5 (3.8–5.3) 0.8 (0.7–1.1)
Obese 104 (8.2) 2017.9 5.2 (4.3–6.2) 1.0 (0.8–1.2)
Anaemic (up to 3 months before or after delivery/baseline)
No 227 (7.7) 4867.3 4.7 (4.1–5.3) 1 1 1 1
Yes 160 (9.8) 2537.3 6.3 (5.4–7.4) 1.4 (1.1–1.7) 1.2 (0.9–1.5) 1.6 (1.1–2.3) 1.0 (0.7–1.6)
CD4þ cell count (up to 3 months before or after delivery/baseline)
Under 200 149 (13.9) 1637.7 9.1 (7.7–10.7) 1 1 1 1
200–349 153 (9.8) 2447.0 6.3 (5.3–7.3) 0.7 (0.5–0.9) 0.6 (0.4–0.9) 1.1 (0.7–1.7) 0.8 (0.5–1.4)
350 or higher 129 (5.5) 3740.7 3.4 (2.9–4.1) 0.4 (0.3–0.5) 0.2 (0.1–0.4) 0.4 (0.3–0.7) 0.5 (0.3–0.9)
CD4þ recovery from date of ART initiation to date of delivery
Decline/no change 105 (9.5) 1684.0 6.2 (5.1–7.5) 1 1 1 1
<99 cell/ml increase 85 (12.0) 1098.3 7.7 (6.3–9.6) 1.2 (0.9–1.7) 1.5 (1.1–2.1) 1.1 (0.5–2.1) 1.6 (0.8–3.0)
100–200 cell/ ml increase 95 (8.8) 1698.3 5.6 (4.6–6.8) 0.9 (0.7–1.2) 1.2 (0.8–1.7) 0.7 (0.4–1.4) 1.3 (0.6–2.6)
>200 cell/ml increase 146 (7.0) 3344.6 4.4 (3.7–5.1) 0.7 (0.5–0.9) 1.3 (0.9–2.0) 1.0 (05–2.0) 1.4 (0.6–3.4)
Unsuppressed viral load (50 copies/ml) up to 3 months before or after delivery (or equivalent matched time)
No 97 (3.1) 5080.1 1.9 (1.6–2.3) 1 1 1 1
Yes 333 (16.9) 2908.6 11.4 (10.2–12.7) 6.0 (4.8–7.5) 42.4 (20.2–89.0) 6.1 (4.2–8.9) 74.4 (11.6–477.5)
3TC, lamivudine; ABC, abacavir; aHR, adjusted hazard ratio; ART, antiretroviral therapy; CI, confidence interval; d4T, stavudine; EFV, efavirenz;
FTC, emtricitabine; HR, hazard ratio; NGO, nongovernmental organizations; NVP, nevirapine; PY, person-years; TDF, tenofovir; ZDV,
zidovudine.4.6–5.5]. Among exposed (postpartum) women, 9.4%
experienced a virologic failure compared with 8.2%
in the unexposed group. The crude incidence rate of
failure was highest among the incident pregnancy group
(5.7/100 person-years, 95% CI: 5.0–6.6) and lower
among the prevalent pregnancy group (4.2/100 person-
years, 95% CI: 3.5–5.0). Although only 16.9% of womenwith unsuppressed baseline viral load went on to fail in the
postpartum period, they were 42.4 times more likely to
fail (95% CI: 20.2–89.0) compared with those who were
suppressed at delivery.
After adjusting for baseline demographics and baseline
viral suppression, women in the incident pregnancy
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Fig. 1. Instantaneous probability of virologic failure during the first 24 months postpartum among HIV-positive women on
antiretroviral therapy in Johannesburg, South Africa.group were at higher risk of virologic failure compared
with unexposed women [adjusted hazard ratio (aHR) 1.3,
95% CI: 1.0–1.8] and to those with a prevalent pregnancy
at ART initiation (aHR 1.8, 95% CI: 1.1–2.7),
particularly among those with baseline CD4þ cell count
less than 350 cells/ml. The hazard for virologic failure was
highest in the first 12 months postpartum and decreased
with time (aHR 1.8, 95% CI: 1.1–3.0) (Fig. 1). Overall,
the risk of failure decreased with older age but increased
with longer duration on ART before delivery/baseline.
When the model was stratified by pregnancy group
(incident vs. prevalent pregnancy), we found that, although
baseline CD4þ cell count and time on ART remained
important predictors across pregnancygroups, agewas only
influential among women in the incident pregnancy group.
Although not statistically significant, women who con-
ceived on ART and delivered after receiving ART for
longer than 12 months (13–24 months, aHR 1.8, 95%
CI: 1.0–3.5) were more likely to experience a failure
compared with those who initiated ART less than
12 months before delivery. Furthermore, women who
initiated ART on regimens that included d4T (aHR 2.3,
95% CI: 1.2–4.4) or ABC (aHR 5.5, 95% CI: 1.1–27.0)
were more likely to fail compared with patients who were
receiving TDF-based regimens. Increased risk of post-
partum virologic failure was also associated with being
anaemic at baseline (aHR 1.6, 95% CI: 1.1–2.3).
In the prevalent pregnancy group, longer antenatal ART
duration also increased the risk of postpartum virologic
failure (aHR 3.0, 95% CI: 1.4–6.2 for those with7 months of antenatal ART compared with3 months).
Similarly, to the incident pregnancy group, among the
prevalent pregnancy group, low CD4þ cell count at
delivery predicted postpartum virologic failure (aHR
0.5, 95% CI: 0.3–0.9 for those with baseline CD4þ
 350 cells/ml compared with CD4þ< 200 cell/ml).
Predictors of being loss to follow-up by
24 months postpartum
Table 3 presents rates and predictors of becoming LTFU
by 24 months postpartum. When the LTFU analysis was
restricted to women with at least one viral load measure
on record, 1482 (23.5%) had become LTFU at a rate of
14.7/100 person-years (95% CI: 14.0–15.5) compared
with 29.3% at a rate of 19.4/100 person-years (95% CI:
18.6–20.3) when all 6825 women with at least one
scheduled visit after delivery were included. To ensure
comparability between the sample in the virologic
failure model, all further LTFU regression analyses were
conducted on the restricted sample of 6306 representing
10 077.4 person-years (mean 1.5 years, SD 0.7) of
observation time. The proportion of LTFU was lower
among women with incident pregnancies (19.5%
compared with 27.7% in the prevalent pregnancy group).
Women in the prevalent pregnancy group had a slightly
higher risk of becoming LTFU compared with unex-
posed women (aHR 1.2, 95% CI: 1.0–1.5) and a similar
risk as women who conceived on ART (aHR 0.9, 95%
CI: 0.7–1.1). The hazard of becoming LTFU increased
sharply in the first 12 postpartum months and remained
relatively stable until about 18 months postpartum
(Fig. 2).
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Fig. 2. Instantaneous probability of becoming loss to follow-
up during the first 24 months postpartum among HIV-
positive women on antiretroviral therapy in Johannesburg,
South Africa.Women in the incident pregnancy group who received
HIV care from an NGO clinic had a lower risk of
becoming LTFU (aHR 0.6, 95% CI: 0.4–1.0) compared
with those from hospital-based clinics, whereas those
who were treated at a local primary care clinic were more
likely to become LTFU (aHR 1.5, 95% CI: 1.1–2.1).
However, having a baseline CD4þ cell count at least 350
cells/ml was associated with a slightly lower risk of
becoming LTFU (hazard ratio 0.7, 95% CI: 0.5–1.1)
compared with those with CD4þ less than 200 cells/ml at
delivery. In addition, women who were unsuppressed at
delivery were 60% more likely to become LTFU (95% CI:
1.2–2.1). In this group, the risk of postpartum LTFU was
not associated with age, education, employment status or
length of time on ART.
Among women in the prevalent pregnancy group, those
who attended some secondary school were more likely to
be lost compared with those who only attended primary
school (aHR 1.6, 95 CI: 1.0–2.7), and being unemployed
marginally increased the risk of becoming LTFU (aHR
1.2, 95% CI: 1.0–1.6). Notably, having received at least
7 months of antenatal ART compared with 3 or less
months was associated with a lower risk of becoming
LTFU (aHR 0.4, 95% CI: 0.2–0.7). CD4þ cell count and
viral suppression at delivery did not predict LTFU in
this group.Discussion
In this article, we show that South African women who
conceive while receiving ART are more likely to
experience a virologic failure postpartum compared with
nonpregnant women and those who initiate ART in
pregnancy. Women who initiate ART in pregnancy have
a slightly higher risk of becoming lost from care afterdelivery compared with nonpregnant women. However,
there was no difference in the risk of becoming LTFU by
24 months when compared with the incident pregnancy
group.
Similar to findings from other sub-Saharan African
settings, we found that 39.8% of postpartum women had
detectable viral RNA at delivery, and 9.4% experienced a
virologic failure in the postpartum period [18–20]. Viral
suppression rates decrease gradually from nonpregnant
state to postpartum period [18]. Although the PMTCT
programme coverage in South Africa has been successful
in nearly eliminating MTCT, postpartum virologic
suppression is the key for further reductions of
postpartum transmission rates [20].
Predictors of postpartum virologic failure among women
who conceived on ART included having a CD4þ less
than 350 cells/ml at delivery, longer periods on ART
before delivery and possible prior experience with
adverse drug reaction (initiating ART on regimens
including ABC or d4T). Low CD4þ cell count at
delivery points to declining health during pregnancy and
perhaps even at conception [21–23]. Westreich et al.
showed an increased risk of virologic failure in pregnancy
among women who conceived on ART, suggesting
persistently poorer viral control during pregnancy as well
as postpartum [24,25]. The incident pregnancy group was
more likely to have had prior ART adherence challenges
as demonstrated by the higher proportion switched to
second-line ART by the time of delivery compared with
the prevalent pregnancy group. This higher risk of failure
may also be because of experiences of drug toxicities and
treatment fatigue as a consequence of being on ART for
longer. Longer period of continuous viral suppression
have been associated with lower risk of virologic failure
[26,27]. Treatment-experienced women with a longer
period of good adherence may be better prepared to
handle adherence challenges postpartum. However,
women who are already prone to nonadherence may
struggle even more postpartum.
In contrast, a similar analysis among HIV-positive
women in the United Kingdom found that women
who initiated ART in pregnancy were more likely to
experience viral rebound at 3 months postpartum
compared with those who conceived on ART [27].
The difference may be in improved monitoring of
patients on ART before and during pregnancy. Our
findings highlight the need to strengthen adherence
counselling and viral load monitoring during pregnancy
to help identify women in need of additional adherence
support postpartum.
The overall proportion of women who became LTFU by
24 months postpartum is considerably lower than
previously reported figures in South African settings
[28,29]. Over 20% of the original sample was excluded
Postpartum virologic failure and loss to follow-up Onoya et al. 1601because of missing postpartum viral load data. This may
have biased the analysis towards women who are more
inclined to enter and remain in postpartum care at the
selected clinics. Our results also potentially underestimate
rates of programmatic losses from care and virologic
failure, which does not bode well for the postpartum risk
of MTCT [30]. This is problematic as the data set only
covered the pre-Option Bþ and ‘treat-all’ policy era
(pre-2015), when only women with low CD4þ cell
count were initiated on lifelong ART for their own
health. Healthier women initiated on lifelong ARTunder
the Option Bþ programme and the ‘treat-all’ policy may
be even less inclined to adhere and remain in care in the
postpartum period [31–34].
Although there was no difference in the risk of becoming
LTFU between the incident and prevalent pregnancy
groups, the difference in predictors of LTFU could be
attributed to the phase of ARTexperience. The incident
pregnancy group most likely consisting of ‘survivors’ of
the initial wave of losses after ART initiation and the
prevalent pregnancy group are in the early stages of their
ART experience. Losses among treatment-experienced
women could be related to health system factors such as
patient management approaches or monitoring data
quality. It is possible that women with low CD4þ cell
count and those who were unsuppressed at delivery were
sicker, and the referrals to higher level healthcare facilities
or even deaths were poorly recorded. In addition, our
analysis is limited by the fact that the data consisted of
routinely collected medical records with unevenly
distributed proportions of missing information. There-
fore, further research is needed to understand the
differences in LTFU across types of sites to further
elaborate on possible retention/data system strengthening
interventions for the PMTCT programme.
Losses among the prevalent pregnancy group are
associated with personal factors (education, unemploy-
ment) that impact on engagement with HIV care both
during and after pregnancy. However, women who
initiated antenatal ART in the first trimester of pregnancy
were more likely to be retained compared with women
who initiated in the last trimester or at delivery. This
highlights an additional benefit of early ART initiation
during pregnancy. Longer ARTexposure also ensures that
women receive repeat counselling and acquire a better
understanding of the risks associated with disengaging
from care.
In conclusion, the results highlight the need to strengthen
adherence-monitoring efforts during pregnancy to
identify women, particularly treatment-experienced
women, who will require further support in the
postpartum phase of the PMTCT programme. Monitor-
ing and evaluation data must account for transfers across
health facilities to better inform retention and follow-up
strategies, and for accurate determinations of LTFU ratesamong postpartum women. Finally, increasing the
demand for early ANC and ART initiation among
treatment-naive HIV-positive women will also have a
positive impact on postpartum LTFU which will, in turn,
contribute to the goals of reducing transmission risks and
promoting the health of new mothers.Acknowledgements
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